Patent US2344111A successfully refreshed from Google Patents.
Patent US4312883A successfully refreshed from Google Patents.
US4312883A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Furocoumarin for the photochemotherapy of psoriasis and related skin diseases
Assignee: Consiglio Nazionale delle Richerche
•
Filing: 1980-08-15
•
Granted: 1982-01-26
•
Expires: 2000-08-15
Abstract
Abstract A class of alkyl-substituted angular flurocoumarins, sometimes termed alkylangelicins, useful in the photochemotherapy of psoriasis and in other skin diseases characterized by cellular hyperproliferation or lack of skin pigmentation is disclosed for topical application or systemic administration. Compared with conventional psoralens the described compounds exhibit a lower risk of skin cancer, absence of phototoxicity problems anderithema to the patient so treated. One preferred compound is 5-methylangelicin.
Inventors
- 👤 Francarosa Baccichetti
- 👤 Franco Bordin
- 👤 Francesco Carlassare
- 👤 Francesco Dall'Acqua
- 👤 Adriano Guiotto
- 👤 Giovanni Pastorini
- 👤 Giovanni Rodighiero
- 👤 Paolo Rodighiero
- 👤 Daniela Vedaldi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 17:21
CPC Classifications
C; C07; C07D; C07D311/00; C07D311/02; C07D311/04; C07D311/06; C07D311/08; C07D311/18; A; A61; A61P; A61P17/00; A61P43/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
91 words
A compound for the photochemotherapy of psoriasis and related skin diseases characterized by cellular hyperproliferation, said compound having the formula: ##STR51## in which R 1 and R 3 , which may be the same or different, are hydrogen, methyl or ethyl; R 2 is hydrogen, methyl or ethyl, and R 4 is methoxymethyl, hydroxymethyl, acetoxymethyl or a group of the formula: ##STR52## wherein R 5 and R 6 are independently hydrogen, methyl or ethyl and n and m are independently an integer of 1 to 3, or a pharmaceutical salt thereof.
Claim 2
Dependent Claim
91 words
A compound for the photochemotherapy of psoriasis and related skin diseases characterized by cellular hyperproliferation, said compound having the formula: ##STR51## in which R 1 and R 3 , which may be the same or different, are hydrogen, methyl or ethyl; R 2 is hydrogen, methyl or ethyl, and R 4 is methoxymethyl, hydroxymethyl, acetoxymethyl or a group of the formula: ##STR52## wherein R 5 and R 6 are independently hydrogen, methyl or ethyl and n and m are independently an integer of 1 to 3, or a pharmaceutical salt thereof.
Claim 3
Dependent Claim
18 words
A furocoumarin selected from the group consisting of: 4,5'-dimethyl-4'-hydroxymethylangelicin, 4,5'-dimethyl-4'-(N,N-diethyl)aminoethoxymethylangelicin, 4'-acetoxymethyl-4,5'-dimethyl-4,5'-dimethylangelicin, 4'-N,N-dimethylethoxymethyl-4,5'-dimethylangelicin or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
18 words
A furocoumarin selected from the group consisting of: 4,5'-dimethyl-4'-hydroxymethylangelicin, 4,5'-dimethyl-4'-(N,N-diethyl)aminoethoxymethylangelicin, 4'-acetoxymethyl-4,5'-dimethyl-4,5'-dimethylangelicin, 4'-N,N-dimethylethoxymethyl-4,5'-dimethylangelicin or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
32 words
A pharmaceutical composition for topical application for the photochemotherapy of psoriasis containing a therapeutically effective amount of a compound of claim 1 or 2 together with an acceptable topical carrier or diluent.
Claim 6
Dependent Claim
22 words
The pharmaceutical composition of claim 3 wherein said compound is present in an amount of from about 0.05 to about 0.4% w/v.
Claim 7
Dependent Claim
29 words
A pharmaceutical composition for the photochemotherapy of psoriasis containing a therapeutically effective amount of a compound of claim 1 or 2 together with a pharmaceutically acceptable carrier or diluent.
Claim 8
Dependent Claim
25 words
The pharmaceutical composition of claim 5 wherein about 30 mg said compound is present and the composition is a tablet or capsule for oral administration.
Claim 9
Dependent Claim
159 words
A photochemotherapeutic method of treating psoriasis or skin disease sensitive to such treatment comprising (a) administering to a person suffering therefrom an effective amount of a compound of the formula: ##STR53## in which R 1 and R 3 , which may be the same or different, are hydrogen, methyl or ethyl; R 2 is hydrogen, methyl, ethyl, methoxy or a group of the formula ##STR54## and R 4 is hydrogen, methyl, ethyl, methoxymethyl, hydroxymethyl, acetoxymethyl or a group of the formula: ##STR55## wherein R 5 and R 6 are independently hydrogen, methyl or ethyl and n and m are independently an integer of 1 to 3, or a pharmaceutical salt thereof, and thereafter (b) irradiating the affected skin area with UV-A light for a period of time sufficient to provide an irradiation dose of about 3 to about 20 J/cm 2 , and (c) repeating steps (a) and then (b) until the psoriasis or skin disease symptoms are ameolerated.
Claim 10
Dependent Claim
159 words
A photochemotherapeutic method of treating psoriasis or skin disease sensitive to such treatment comprising (a) administering to a person suffering therefrom an effective amount of a compound of the formula: ##STR53## in which R 1 and R 3 , which may be the same or different, are hydrogen, methyl or ethyl; R 2 is hydrogen, methyl, ethyl, methoxy or a group of the formula ##STR54## and R 4 is hydrogen, methyl, ethyl, methoxymethyl, hydroxymethyl, acetoxymethyl or a group of the formula: ##STR55## wherein R 5 and R 6 are independently hydrogen, methyl or ethyl and n and m are independently an integer of 1 to 3, or a pharmaceutical salt thereof, and thereafter (b) irradiating the affected skin area with UV-A light for a period of time sufficient to provide an irradiation dose of about 3 to about 20 J/cm 2 , and (c) repeating steps (a) and then (b) until the psoriasis or skin disease symptoms are ameolerated.
Claim 11
Dependent Claim
45 words
The method of claim 7 wherein the compound is administered in step (a) is applied directly to the affected skin area in the form of a topically applied pharmaceutical composition and the topically applied pharmaceutical composition remains in contact with the skin during step (b).
Claim 12
Dependent Claim
38 words
The method of claim 8 wherein the topically applied pharmaceutical composition is applied in step (a) and irradiated in step (b) from about 3 to about 5 times per week for a period of at least two weeks.
Claim 13
Dependent Claim
48 words
The method of claim 7 wherein the compound in step (a) is administered orally and the time period between step (a) and the irradiation step (b) is between about 2 to 3 hours until the orally administered compound is localized at the site of psoriasis or skin disease.
Claim 14
Dependent Claim
18 words
The method of claim 7, 8, 9 or 10 wheein the compound is: 5-methylangelicin, 4,5'-dimethylangelicin, 4'-hydroxymethyl-4,5'-dimethylangelicin or 4,5-dimethylangelicin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-25 | 1985-07-27 | 1986-01-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-25 | 1989-07-27 | 1990-01-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-25 | 1993-07-27 | 1994-01-26 | $7700.00 | Window Closed / Lapsed |